BACKGROUND: In many centers, 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is used to monitor treatment response after definitive (chemo)radiotherapy [(C)RT] for head and neck squamous cell carcinoma (HNSCC), but its usefulness remains somewhat controversial. We aimed at assessing the accuracy of FDG-PET/CT in detecting residual disease after (C)RT.

METHOD: All HNSCC patients with FDG-PET/CT performed to assess treatment response 10–18 weeks after definitive (C)RT at our institution during 2008–2010 were included. The patient charts were reviewed for FDG-PET/CT findings, histopathologic findings, and follow-up data. The median follow-up time for FDG-PET/CT negative patients was 26 months.

Continue Reading

RESULTS: Eighty-eight eligible patients were identified. The stage distribution was as follows: I, = 1; II, = 15; III, = 17; IV, = 55. The negative predictive value, positive predictive value, specificity, sensitivity, and accuracy of FDG-PET/CT in detecting residual disease were 87%, 81%, 94%, 65%, and 85%, respectively. The corresponding specific figures for the primary tumor site were 91%, 71%, 94%, 59%, and 86% and for the neck 93%, 100%, 100%, 75%, and 94%, respectively.

CONCLUSIONSIn patients who have received definitive (C)RT for HNSCC, post-treatment FDG-PET/CT has good potential to guide clinical decision-making. Patients with negative scan can safely be followed up clinically only, while positive scan necessitates tissue biopsies or a neck dissection to rule out residual disease.

KEYWORDS: FDG-PET/CT, head and neck squamous cell carcinoma, HNSCC, chemoradiotherapy, response assessment

CITATION: Keski-säntti et al. Fdg-Pet/Ct in the assessment of treatment response after oncologic treatment of head and neck squamous Cell Carcinoma. Clinical Medicine Insights: Ear, Nose and Throat 2014:725 –729. doi:10.4137/CMent.s16399.

RECEIVED: april 23, 2014. RESUBMITTED: June 7, 2014. ACCEPTED FOR PUBLICATION: June 8, 2014.

ACADEMIC EDITOR: Brenda Anne Wilson, editor in Chief

TYPE: original research

FUNDING: authors disclose no funding sources.

COMPETING INTERESTS: Authors disclose no potential conflicts of interest.

COPYRIGHT: © the authors, publisher and licensee Libertas Academica limited. this is an open-access article distributed under the terms of the Creative Commons CC-BY-nC 3.0 license.

CORRESPONDENCE: [email protected]

This paper was subject to independent, expert peer review by a minimum of two blind peer reviewers. all editorial decisions were made by the independent academic editor. all authors have provided signed confirmation of their compliance with ethical and legal obligations including (but not limited to) use of any copyrighted material, compliance with ICMJE authorship and competing interests disclosure guidelines and, where applicable, compliance with legal and ethical guidelines on human and animal research participants. the preliminary results of this study were presented at the 5th european Conference on head and neck oncology, Poznan, Poland, april 18–21, 2012.